WINT Quote, Financials, Valuation and Earnings

AIM ImmunoTech has a net margin of -- compared to Windtree Therapeutics's net margin of -10571.43%. Windtree Therapeutics's return on equity of -- beat AIM ImmunoTech's return on equity of -256.33%.

Windtree Therapeutics has a consensus price target of $4.00, signalling upside risk potential of 344.44%. On the other hand AIM ImmunoTech has an analysts' consensus of $4.50 which suggests that it could grow by 11066.25%. Given that AIM ImmunoTech has higher upside potential than Windtree Therapeutics, analysts believe AIM ImmunoTech is more attractive than Windtree Therapeutics.

Windtree Therapeutics has a beta of 0.703, which suggesting that the stock is 29.741% less volatile than S&P 500. In comparison AIM ImmunoTech has a beta of 0.760, suggesting its less volatile than the S&P 500 by 23.953%.

Windtree Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. AIM ImmunoTech offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Windtree Therapeutics pays -- of its earnings as a dividend. AIM ImmunoTech pays out -- of its earnings as a dividend.

Windtree Therapeutics quarterly revenues are --, which are smaller than AIM ImmunoTech quarterly revenues of $35K. Windtree Therapeutics's net income of -$4M is lower than AIM ImmunoTech's net income of -$3.7M. Notably, Windtree Therapeutics's price-to-earnings ratio is -- while AIM ImmunoTech's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Windtree Therapeutics is 0.42x versus 13.27x for AIM ImmunoTech. Usually stocks with elevated PS ratios are considered overvalued.

Armata Pharmaceuticals has a net margin of -- compared to Windtree Therapeutics's net margin of --. Windtree Therapeutics's return on equity of -- beat Armata Pharmaceuticals's return on equity of --.

Windtree Therapeutics has a consensus price target of $4.00, signalling upside risk potential of 344.44%. On the other hand Armata Pharmaceuticals has an analysts' consensus of $9.00 which suggests that it could grow by 281.36%. Given that Windtree Therapeutics has higher upside potential than Armata Pharmaceuticals, analysts believe Windtree Therapeutics is more attractive than Armata Pharmaceuticals.

Windtree Therapeutics has a beta of 0.703, which suggesting that the stock is 29.741% less volatile than S&P 500. In comparison Armata Pharmaceuticals has a beta of 0.938, suggesting its less volatile than the S&P 500 by 6.224%.

Windtree Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Armata Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Windtree Therapeutics pays -- of its earnings as a dividend. Armata Pharmaceuticals pays out -- of its earnings as a dividend.

Windtree Therapeutics quarterly revenues are --, which are smaller than Armata Pharmaceuticals quarterly revenues of --. Windtree Therapeutics's net income of -$4M is higher than Armata Pharmaceuticals's net income of -$6.5M. Notably, Windtree Therapeutics's price-to-earnings ratio is -- while Armata Pharmaceuticals's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Windtree Therapeutics is 0.42x versus 1,000.03x for Armata Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.

Inovio Pharmaceuticals has a net margin of -- compared to Windtree Therapeutics's net margin of -30140.49%. Windtree Therapeutics's return on equity of -- beat Inovio Pharmaceuticals's return on equity of -125.47%.

Windtree Therapeutics has a consensus price target of $4.00, signalling upside risk potential of 344.44%. On the other hand Inovio Pharmaceuticals has an analysts' consensus of $7.50 which suggests that it could grow by 459.7%. Given that Inovio Pharmaceuticals has higher upside potential than Windtree Therapeutics, analysts believe Inovio Pharmaceuticals is more attractive than Windtree Therapeutics.

Windtree Therapeutics has a beta of 0.703, which suggesting that the stock is 29.741% less volatile than S&P 500. In comparison Inovio Pharmaceuticals has a beta of 1.307, suggesting its more volatile than the S&P 500 by 30.734%.

Windtree Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Inovio Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Windtree Therapeutics pays -- of its earnings as a dividend. Inovio Pharmaceuticals pays out -- of its earnings as a dividend.

Windtree Therapeutics quarterly revenues are --, which are smaller than Inovio Pharmaceuticals quarterly revenues of $65.3K. Windtree Therapeutics's net income of -$4M is higher than Inovio Pharmaceuticals's net income of -$19.7M. Notably, Windtree Therapeutics's price-to-earnings ratio is -- while Inovio Pharmaceuticals's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Windtree Therapeutics is 0.42x versus -- for Inovio Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.

Protalix BioTherapeutics has a net margin of -- compared to Windtree Therapeutics's net margin of -35.79%. Windtree Therapeutics's return on equity of -- beat Protalix BioTherapeutics's return on equity of 10.9%.

Windtree Therapeutics has a consensus price target of $4.00, signalling upside risk potential of 344.44%. On the other hand Protalix BioTherapeutics has an analysts' consensus of $14.00 which suggests that it could grow by 879.02%. Given that Protalix BioTherapeutics has higher upside potential than Windtree Therapeutics, analysts believe Protalix BioTherapeutics is more attractive than Windtree Therapeutics.

Windtree Therapeutics has a beta of 0.703, which suggesting that the stock is 29.741% less volatile than S&P 500. In comparison Protalix BioTherapeutics has a beta of -0.227, suggesting its less volatile than the S&P 500 by 122.694%.

Windtree Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Protalix BioTherapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Windtree Therapeutics pays -- of its earnings as a dividend. Protalix BioTherapeutics pays out -- of its earnings as a dividend.

Windtree Therapeutics quarterly revenues are --, which are smaller than Protalix BioTherapeutics quarterly revenues of $10.1M. Windtree Therapeutics's net income of -$4M is lower than Protalix BioTherapeutics's net income of -$3.6M. Notably, Windtree Therapeutics's price-to-earnings ratio is -- while Protalix BioTherapeutics's PE ratio is 35.75x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Windtree Therapeutics is 0.42x versus 2.01x for Protalix BioTherapeutics. Usually stocks with elevated PS ratios are considered overvalued.